Key areas of investigation include expanding drug targets, stem cell therapies to regenerate insulin-producing beta cells in T1DM, microbiome-based interventions, and gene therapies for monogenic forms of obesity and diabetes [21]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.